Literature DB >> 10505287

Acute myocardial infarction with cardiogenic shock on admission: incidence, prognostic implications, and current treatment strategies. Results from "the 60-Minutes Myocardial Infarction Project". ALKK ("Arbeitsgemeinschaft leitender Krankenhauskardiologen") Study Group.

W Beermann1, J Carlsson, J Rustige, R Schiele, J Senges, U Tebbe.   

Abstract

Little data exist about current treatment strategies the efficacy of thrombolytic therapy and outcome of patients with acute myocardial infarction (AMI) presenting in cardiogenic shock (CS). Data from the German multicenter "60 Minutes Myocardial Infarction Project" were used to analyze a large number of patients with AMI and CS on admission and to compare those to patients without CS. Between July 1993 and September 1994 a total of 7,085 patients with AMI were registered. Out of these, 179 patients (2.5%) presented in CS (systolic blood pressure < 100 and heart rate > 100/min, resuscitated patients were excluded). Patients in CS were significantly older than patients without CS. Their in-hospital mortality was 47.1% compared with 12.4% in patients without CS (p = 0.001). The prevalence of the following clinical parameters was significantly higher in patients with CS than in those without CS: bundle branch block, prior MI, and a non-diagnostic ECG (all p < 0.05). Thrombolytic therapy was used in 36.3% of patients in CS and in 50.8% of those without CS (p = 0.001). The in-hospital mortality in patients with CS receiving thrombolytic therapy was significantly lower than in patients with CS who did not receive thrombolytic agents (33.3% versus 55.1%; p = 0.006). In daily clinical practice in Germany thrombolytic treatment is used in only 36.3% of patients with AMI presenting in CS on admission. The use of thrombolysis in CS on admission is associated with a lower in-hospital mortality.

Entities:  

Mesh:

Year:  1999        PMID: 10505287     DOI: 10.1007/BF03043928

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  26 in total

1.  Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival.

Authors:  L Lee; R Erbel; T M Brown; N Laufer; J Meyer; W W O'Neill
Journal:  J Am Coll Cardiol       Date:  1991-03-01       Impact factor: 24.094

2.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

3.  Myocardial changes associated with cardiogenic shock.

Authors:  D L Page; J B Caulfield; J A Kastor; R W DeSanctis; C A Sanders
Journal:  N Engl J Med       Date:  1971-07-15       Impact factor: 91.245

4.  Shock after acute myocardial infarction. A clinical and hemodynamic profile.

Authors:  S Scheidt; R Ascheim; T Killip
Journal:  Am J Cardiol       Date:  1970-12       Impact factor: 2.778

5.  Progressive nature of myocardial injury in selected patients with cardiogenic shock.

Authors:  A L Gutovitz; B E Sobel; R Roberts
Journal:  Am J Cardiol       Date:  1978-03       Impact factor: 2.778

Review 6.  Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock.

Authors:  M D Hibbard; D R Holmes; K R Bailey; G S Reeder; J F Bresnahan; B J Gersh
Journal:  J Am Coll Cardiol       Date:  1992-03-01       Impact factor: 24.094

7.  Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock.

Authors:  R C Becker
Journal:  Am Heart J       Date:  1993-03       Impact factor: 4.749

8.  Reduced in-hospital mortality from acute myocardial infarction with general adoption of thrombolytic treatment in the North West Thames health region 1979-1991.

Authors:  R A Greenbaum; R Morris; P Sritara; D Shanit; K L Chan
Journal:  Br Heart J       Date:  1995-11

9.  In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

View more
  1 in total

Review 1.  [Reperfusion therapy and mechanical circulatory support in patients in cardiogenic shock].

Authors:  K H Scholz
Journal:  Herz       Date:  1999-10       Impact factor: 1.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.